Print this page    •   Back to Web version of article

U.S. News
Mylan Receives U.S. Approval for HIV/AIDS Treatment

September 22, 2011

Canonsburg, Pa.-based Mylan Inc. said Tuesday it has received tentative US approval for a generic version of an HIV treatment regimen. Included in the regimen are generic versions of GlaxoSmithKline PLC's Epivir (lamivudine), Gilead Sciences Inc.'s Viread (tenofovir), and Boehringer Ingelheim's Viramune (nevirapine). Mylan said its subsidiary, Matrix Laboratories Ltd., received clearance from the Food and Drug Administration through the President's Emergency Plan for AIDS Relief. Eligible for sale outside the United States, the regimen will be offered in some developing nations.

Back to other news for September 2011

Excerpted from:
Associated Press
09.20.2011




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/64085/mylan-receives-us-approval-for-hivaids-treatment.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.